Polyrizon Ltd. ( (PLRZ) ) has provided an update.
On March 14, 2025, Polyrizon Ltd. announced a non-binding Letter of Intent with a biotech company focused on psychedelic-derived therapeutics to develop a novel intranasal formulation for psychedelic-based treatments. This collaboration aims to leverage Polyrizon’s proprietary platform to enhance the delivery and efficacy of psychedelic treatments, potentially leading to further clinical development and commercialization. The psychedelic company will fund the research and development, with Polyrizon leading the formulation’s development, and intends to negotiate a definitive agreement following proof of concept.
More about Polyrizon Ltd.
Polyrizon Ltd. is a development stage biotech company specializing in innovative medical device hydrogels delivered as nasal sprays. These hydrogels form a protective barrier in the nasal cavity, potentially shielding against viruses and allergens. The company is also developing technologies for nasal delivery of active pharmaceutical ingredients.
YTD Price Performance: -62.84%
Average Trading Volume: 3,016,421
Technical Sentiment Consensus Rating: Strong Buy
For a thorough assessment of PLRZ stock, go to TipRanks’ Stock Analysis page.